Pharmacologic treatment of atrophic age-related macular degeneration
Pharmacologic treatment of atrophic age-related macular degeneration
复制标题
DOI：
10.1097/icu.0b013e32833866c8
复制
发表时间：
2010-05-01
影响因子：
3.7
通讯作者：
Vogel, Roger
中科院分区：
文献类型：
--
作者：
Mata, Nathan L.;Vogel, Roger
综述目的：回顾和比较针对年龄相关性黄斑变性地理性萎缩的各种治疗平台、研究药物和临床试验。最近的发现基于假设原因的研究性药物正在开发用于治疗地理萎缩。这些平台旨在从几个不同的方面打击这种疾病。随着地理萎缩病理生理学知识的进步，靶向药物治疗可能能够减轻与地理萎缩相关的视网膜损伤和视力丧失。
Purpose of reviewTo review and compare the various therapeutic platforms, investigational drugs, and clinical trials targeting geographic atrophy in age-related macular degeneration.Recent findingsInvestigational agents based on hypothesized causes are being developed to treat geographic atrophy. These platforms are designed to attack the disease on several different fronts.SummaryAs knowledge of geographic atrophy pathophysiology advances, targeted pharmacotherapies may well be able to mitigate the retinal damage and vision loss associated with geographic atrophy.